Renalytix Share Discussion Threads

[9degrees] 02/1/2019 10:53

How can Chris mills buy shares when Barclays smart investor says not available ?
Is this share not available to Pi's until 22 april ?

[wan] 02/1/2019 08:35

I thought Renalytix would exercise that option, and strong IP is obviously a very important aspect, especially for small companies! I expect large pharma to be very interested in this fast evolving area of AI in kidney disease, where determining specific immunosuppression therapy levels is also being targeted and developed.

[wan] 21/12/2018 07:38

I note the share prices has been a bit erratic recently, which I thought the arrangements were meant to avoid! Anyway, I also note that Chris Mills has been taking advantage and added more shares to his already significant holding.

[wilsonst1] 07/12/2018 08:47

Interesting. Ta

[wan] 07/12/2018 08:08

Looks like Renalytix is ahead of the game with their Mount Sinai Health System partnership, not to mention proprietary prognostic biomarkers, which would appear to be a differentiating factor. That aside, the US appears to be seriously addressing and delivering what is needed (as other governments are) to accommodate not just the potential of AI in healthcare, but delivery from AI in healthcare!

December 05, 2018 -
Rucker: Without APIs, Artificial Intelligence Will Fail in Healthcare
The success of artificial intelligence in healthcare depends on the widespread adoption of open APIs, says National Coordinator Dr. Don Rucker.

As the healthcare industry looks just over the horizon to a busy, eventful, and competitive 2019, artificial intelligence tools are likely to take on an increasingly important role across the care continuum.

Payers, providers, and health IT developers are pinning many of their hopes for lower costs and better outcomes on AI’s ability to recognize subtle patterns in huge volumes of data, streamline workflows, or suggest actions likely to produce better future results.

For the Office of the National Coordinator (ONC), which is responsible for encouraging health IT adoption and fostering meaningful interoperability, artificial intelligence is both promising and potentially problematic.

Machine learning certainly offers unparalleled possibilities to turn the industry’s big data assets into actionable insights, says National Coordinator Don Rucker, MD, and the ONC is confident that AI will play a major part in improving the delivery of care.

But stakeholders may find it challenging to rapidly develop the technical foundations required to support AI, particularly the open application programming interfaces (APIs) that will allow organizations to feed data-hungry algorithms in a secure and standardized manner.

However, that doesn’t mean that APIs should create a sudden data free-for-all, he added.

“I want to be clear that APIs aren’t just an open door to do whatever you want with data,” Rucker stressed. “Anyone exchanging protected health data through an API is still bound by HIPAA, and they still have to seek appropriate consents from individuals to use their data for analytics or research.”

Privacy and security are not the only challenges facing artificial intelligence developers who want to take advantage of APIs.

Currently, healthcare-specific APIs only allow applications to draw on data at the individual level, Rucker explained.

At some point during 2019, the group expects to be able to offer the industry the ability to transfer larger volumes of health data through the FHIR protocols.

“These population-level queries are designed to use generally the same data structures and approaches as the individual queries we can complete, but scaled up to industrial strength,” said Rucker. “That's a critical building block for AI.”

Once the capability is sufficiently developed and turned loose in the healthcare environment, Rucker believes that uptake will be swift and decisive, ushering in a new generation of AI opportunities.

“I believe that within the next two years, we’re going to be using that ability broadly throughout the healthcare industry, and it is going to be revolutionary in many ways,” he predicted.

“We have to be able to do this quickly. If we can't find a way to use APIs to their full capacity, then AI is simply not going to be operationalized in healthcare.”

Full story -

[advfn_sales] 22/11/2018 14:01

Here is the chance to meet with Renalytix:

Using this unique discount code, ADVFN25, you will be able to get £25 off at Mello London 2018, a 2 day investor conference from the 26th – 27th November 2018 at the Clayton Hotel, Chiswick, London.



Tickets are normally priced at £99 for two days and £79 for one.

Type in ADVFN25 as the discount code.

Many Thanks and take advantage of this premium offer.

[the stigologist] 21/11/2018 19:41

The recent listings of Sensyne (SENS) (formerly known as Drayson Health) and Renalytix (RENX) have focused attention of UK investors on the new AI MedTech sector.

Companies such as this in the AI/Machine Learning MedTech space "use anonymised data from the NHS to diagnose patterns in cancer and other diseases ...then pass on findings to drug companies so they can develop treatments faster and more cost-effectively than in the past."

The rich valuations enjoyed by SENS and RENX have caused investors to look for other companies in the sector which may be 'hidden gems'. One such is Physiomics (PYC).

Whilst Sensyne and Renalytix are valued at £240m and £70m despite have zero in revenues Physiomics is valued at only £3m AND has revenues of c. £0.5m

However when considering how to value Physiomics it's important to realise there are two major strands to it's business.

One strand is its 'legacy' Modelling and Simulation business which last year signed a E0.5m deal with Merck KgGA. This part of the business is analagous to the likes of Simulations Plus a $400m Mkt Cap Nasdaq listed comparitor with c.$20m in revenues. Thus one could apply a 'rating' of 10-20x revenues to value Physiomics business in this area. (£0.4m x 10-20x = £4.0-8.0m)

The new strand to Physiomics business is it's AI/Personalised Medicine business. In this part of the business Physiomics has won research grant funding from the UK Government's InnovateUK to progress several studies on specific cancers in association with Oxford University academics and Oxford NHS.

e.g.

Oesophagal Cancer study

Prostate Cancer study


This part of Physiomics business is similar to and should be valued with reference to its newly listed comparitors Renalytix (RENX) and Sensyne (SENS). Those valuations would suggest a very wide potential range from £70m to £240m.

Putting together the 'sum of the parts' we can conclude that a case can be made for valuing Physiomics currently as 'worth' somewhere within a range of £74-248m.

In terms of share price with 72m shares in issue this would imply a potential valuation range of c.100-350p

Clearly at a mere 5p the market has a lot of catching up to do in valuing Physiomics correctly.

[the stigologist] 09/11/2018 09:59

PYC (4p ; Mkt Cap £3m)

The case for a moonshoot spike to 100p is now inescapable after recent listing of AI biomedtech comparitors SENS and RENX

SENS (Sensyne) Mkt Cap £240m Rev : £0m
RENX (Renalytix) Mkt Cap £70m Rev : £0m
PYC (Physiomics) Mkt Cap £3m Rev : £0.5m

[cambridgedon] 08/11/2018 17:10

In the absence of ADVFN posting RNS announcements; I note that Lombard Odier A M bought 5.82% on the 6th.

CD

[cambridgedon] 08/11/2018 09:46

When should the free shares show up in our accounts? Nothing showing at A J Bell. I've written to ask when, but no response yet.
Good to see a RENX director buying another 16,150 yesterday.
CD

[the stigologist] 06/11/2018 22:28

Chart should feed in once advfn have got their act together at the back end

[cambridgedon] 06/11/2018 12:59

Please can someone set up a chart?
I would, but don't know how.

CD

[the stigologist] 06/11/2018 07:39

Renalytix AI plc (AIM: RENX), a developer of artificial intelligence ("AI") enabled clinical diagnostic solutions for kidney disease, announces the admission of its ordinary shares ("Ordinary Shares") to trading on AIM ("Admission"). Dealings in the Ordinary Shares will commence today under the ticker "RENX" and ISIN GB00BYWL4Y04.

The Company's Admission Document is available from www.renalytixai.com/investors

Transaction highlights

· £22.25 million raised through a placing, US subscription and restricted offer to shareholders of EKF Diagnostics Holdings plc ("EKF") (the "Fundraising") at a price £1.21 per Ordinary Share (the "Issue Price")

· 53,816,134 Ordinary Shares in issue at Admission

· The Ordinary Shares issued in connection with the Fundraising represent c. 34.2% of the enlarged share capital of the Company at Admission

· £65.12 million market capitalisation on Admission at the Issue Price

· N+1 Singer acted as placing agent and is retained as Nominated Adviser and Broker to RenalytixAI